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  We examine whether Phellodendron amurense (PA) and its major alkaloid compound, berberine 
(BER), improved memory defects caused by administering scopolamine in rats. Effects of PA and BER 
on the acetylcholinergic system and pro-inflammatory cytokines in the hippocampus were also investi-
gated. Male rats were administered daily doses for 14 days of PA (100 and 200 mg/kg, i.p.) and BER 
(20 mg/kg, i.p.) 30 min before scopolamine injection (2 mg/kg, i.p.). Daily administration of PA and 
BER improved memory impairment as measured by the passive avoidance test and reduced the escape 
latency for finding the platform in the Morris water maze test. Administration of PA and BER 
significantly alleviated memory-associated decreases in cholinergic immunoreactivity and restored 
brain-derived neurotrophic factor and cAMP-response element-binding protein mRNA expression in the 
hippocampus. PA and BER also decreased significantly the expression of proinflammatory cytokines 
such as interleukin-1β, tumor necrosis factor-α and cyclooxygenase-2 mRNA in the hippocampus. These 
results demonstrated that PA and BER had significant neuroprotective effects against neuronal 
impairment and memory dysfunction caused by scopolamine in rats. These results suggest that PA 
and BER may be useful as therapeutic agents for improving cognitive functioning by stimulating 
cholinergic enzyme activity and alleviating inflammatory responses.
Key Words: Scopolamine, Memory, Cholinergic neurons, Brain-derived neurotrophic factor, Proinflam-
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INTRODUCTION
  Alzheimer’s disease (AD), which is characterized by a pro-
gressive decline in cognitive functioning due to degeneration 
of the cholinergic nervous system and neuronal dysfunction, 
is one of the most common forms of dementia in the aging 
population [1]. In discussions of the neuropathological fea-
tures of memory loss and cognitive dysfunction, as observed 
primarily, in patients with AD, cholinergic deficits and neu-
ronal dysfunction have been considered a primary causes 
[2]. Accordingly, various cholinergic drugs have been appro-
ved to treat AD, and they exert their therapeutic effects 
by counteracting acetylcholine (ACh) deficits and consequen-
tly enhancing the ACh levels in the brain [3]. 
  In the present study, intraperitoneal (i.p.) administration 
of the muscarinic antagonist scopolamine (SCO), a blocker 
of muscarinic ACh receptors, was exploited as a pharmaco-
logical model for AD in rats. SCO induces dysregulation 
of the cholinergic neuronal pathway and memory circuits 
in the central nervous system (CNS), resulting in serious 
impairments in learning, acquisition, and short-term reten-
tion of spatial memory tasks [4]. Because such lesions in 
cholinergic neuronal circuits result in decreased ACh release 
and subsequent dysfunction in learning and memory, the 
SCO-induced amnesic model has been widely used to provide 80 B Lee, et al
a model system of memory dysfunction to screen for phar-
macological agents with memory-enhancing activities [5]. 
  Inflammation, as well as cholinergic neuronal degener-
ation, may play an important role in the pathogenesis of 
the degenerative changes and cognitive impairment asso-
ciated with AD. Proinflammatory cytokines, such as inter-
leukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are 
upregulated in the AD brain [6]. These inflammatory cyto-
kines may play a role as neurotoxic agents in the patho-
logical cascade of AD [7]. 
  Many studies have reported that the use of herbal medi-
cine or natural products in treating Alzheimer type-de-
mentia patients improved their memory related symptoms 
[8,9]. However, there has been little scientific evidence re-
ported regarding their effectiveness or mechanisms of their 
action. 
  Phellodendron amurense (PA) has been widely used in 
Korean traditional medicine to treat bacterial infection of 
the respiratory system and chronic inflammatory diseases 
[10]. PA and its major alkaloid compound, berberine (BER), 
have multiple pharmacological actions and produce a varie-
ty of biological effects in the CNS [11]. In particular, BER 
has been reported to improve diabetes-induced memory im-
pairment and to reduce oxidative stress [12]. Several stud-
ies have shown that BER was effective in ameliorating spa-
tial memory impairment and decreasing the expression of 
IL-1β in a rat model of AD [13], suggesting that the anti-in-
flammatory effects of PA and BER may result from their 
ability to inhibit the degeneration of cholinergic neurons, 
thereby alleviating deficits in spatial learning ability in the 
memory-impairment animal model [14]. 
  The aim of the present study was to evaluate the ability 
of PA and BER to improve learning and memory in rats 
exposed to repeated SCO-induced memory deficits as meas-
ured by performance on the passive avoidance test (PAT) 
and the Morris water maze (MWM) test. Moreover, we ex-
amined how these effects were related to the cholinergic 
system and to anti-inflammatory effects to determine the 
neural mechanisms underlying the memory-enhancing acti-
vity of PA and its main alkaloid compound, BER.
METHODS
Animals 
  Adult male Sprague-Dawley (SD) rats weighing 260∼280 
g were obtained from Samtako Animal Co. (Seoul, Korea). 
The rats were housed in a limited-access rodent facility 
with up to five rats per polycarbonate cage. The room con-
trols were set to maintain the temperature at 22±2
oC and 
the relative humidity at 55±15%. Cages were lit by artificial 
light for 12 h each day. Sterilized drinking water and stand-
ard chow diet were supplied ad libitum to each cage during 
the experiments. The animal experiments were conducted 
in accordance with the Guide for the Care and Use of Labo-
ratory Animals (NIH Publications No. 80-23), revised in 
1996, and were approved by the Kyung Hee University Ins-
titutional Animal Care and Use Committee. All animal ex-
periments began at least 7 days after the animals arrived.
Main reagent
  Scopolamine hydrobromide, tacrine (TA) and BER were 
obtained from standard commercial suppliers (Sigma-Aldrich 
Chemical Co., St Louis, MO, USA). PA, used in this study, 
was purchase from an oriental drug store (Health maxi-
mum Co., Jecheon, Korea). A voucher specimen of PA has 
been deposited at the herbarium located at the College of 
Oriental Medicine, Kyung Hee University (Code number 
KH-PA01 for PA), according to described previous study [15]. 
One hundred grams of PA were cut into small pieces and 
extracted three times with 4 l of 85% methanol by soni-
cation in a reflux condenser for 24 h at room temperature 
(25±2
oC). The extracted solutions were combined, filtered 
through Whatman No. 1 filter paper, concentrated using 
a rotary vacuum evaporator (EYELA CCA-1110, Tokyo 
Rikakikai Co., Tokyo, Japan) to obtain concentrated extracts, 
and then lyophilized (EYELA FD-800). The final yield of 
PA in a powder form was 13.7% (w/w). 
Experimental groups
  To develop learning and memory deficits, male rats were 
intraperitoneally injected at 2 mg/kg body weight with SCO, 
dissolved in physiological saline solution, once a day for 14 
days. Normal animals received saline instead of SCO as 
a vehicle. Different rats in an experimental group were sub-
jected to either behavioral testing or immunohistochemistry. 
The rats were randomly divided into seven groups of seven 
individuals as follows: normal group (SAL group, n=7), the 
saline-induced plus 200 mg/kg PA-treated group (PA group, 
n=7), the SCO-induced and saline-treated group (SCO group 
as a control, n=7), the SCO-induced plus 20 mg/kg BER- 
treated group (SCO＋BER20 group, n=7), the SCO-induced 
plus 100 mg/kg PA-treated group (SCO＋PA100 group, n=7), 
the SCO-induced plus 200 mg/kg PA-treated group (SCO＋
PA200 group, n=7), and the SCO-induced plus 0.2 mg/kg 
TA-treated group (SCO＋TA group, n=7). TA, a centrally 
acting cholinesterase inhibitor, was used as a positive 
control. The rats were intraperitoneally administrated with 
PA and BER once a day for 14 days, and PA and BER were 
dissolved in 0.9% physiological saline. Thirty minutes after 
PA and BER administration, all rats except SAL group 
were received the SCO injection. When starting 9th day af-
ter SCO injection, rats performed to take the MWM task. 
The experimental schedule of all drug administration and 
behavioral tests are shown in Fig. 1.
Passive avoidance test
  All animals were subjected to a passive avoidance test. 
The test was basically performed according to the step- 
through method described previously [16]. The Gemini 
Avoidance System (SD Instruments., San Diego, CA, USA) 
was used for this experiment. Basically, the step-through 
passive avoidance apparatus consists of a two-compartment 
acrylic box with a lightened compartment connected to a 
darkened one by an automatic guillotine door. Electric shock 
was delivered to the grid floor of both compartment, made 
of stainless steel rods (3 mm diameter) spaced 1 cm apart, 
by an isolated shock generator (Behbood Pardaz Co., Ghaem, 
Iran). First, rats were taken trials to acquisition test in the 
apparatus. In this trial, rats were placed in a lightened 
compartment for 300 s, and then the guillotine door was 
opened. Rats have native preference to the dark environ-
ment. Immediately upon entering the dark compartment, 
the door was closed. Acquisition test was recorded the la-
tencies times for entering the dark compartment. After 30 
min, rats were again placed in the lightened compartment. Effect of PA and BER on Memory Impairment 81
Fig. 1. Experimental schedules of 
scopolamine-induced spatial memory
impairments in the rats. Exp 1 was 
designed to explore the efficacy of 
PA and BER administration for 
amelioration of memory impairment 
in an animal model using a passive 
avoidance test (PAT) and immuno-
histochemistry. Exp 2 was designed 
to explore the efficacy of PA and 
BER administration for amelioration
of memory impairment in an animal 
model using the Morris water maze 
(MWM) test, ELISA and RT-RCT 
analyses. 
Rats had spontaneously entered the dark compartment, the 
guillotine door was closed and a mild electrical shock (0.5 
mA) was applied for 3 s. Exactly 24 h after the acquisition 
trial for training, the retention test was performed. The rat 
was again placed in the lightened compartment and the 
guillotine door was opened. The retention test was meas-
ured the latencies times for entering the dark compartment 
in a same method with acquisition test. The maximum en-
try latency allowed in the retention test was 180 s [17].
Morris water maze test 
1. Morris water maze apparatus
  The MWM test was performed using a polypropylene cir-
cular pool (painted white internally, 2.0 m in diameter and 
0.35 m high). The pool contained water maintained at a 
temperature of 22±2
oC. The water was made opaque by 
adding 1 kg of skim milk powder. During the MWM test, 
a platform 15 cm in diameter was located 1.5 cm below the 
water in one of four sections of the pool, approximately 50 
cm from the sidewalls. The pool was surrounded by many 
cues external to the maze. The pool was divided into four 
quadrants of equal area. A digital camera was mounted to 
the ceiling above the pool and was connected to a compu-
terized recording system equipped with a tracking program 
(S-MART: PanLab Co., Barcelona, Spain), which permitted 
on- and off-line automated tracking of the paths taken by 
the rats. 
2. Hidden platform trial for acquisition test
  The MWM test was initiated on the 9
th day after the PA, 
BER and SCO administration commenced. The animals re-
ceived three trials per day. The rats were trained to find 
the hidden platform, which remained in a fixed location 
throughout the test. The trials lasted for a maximum of 
180 s, and the time it took to find the submerged platform 
was recorded each time. The animals were tested three tri-
als per day for 5 days, and they received a 60-s probe trial 
on the sixth day. Finding the platform was defined as stay-
ing on it for at least 4 s before the acquisition time of 180 
s ended. If the rat failed to find the platform in the allotted 
time in first trial of hidden platform test, those rats should 
placed onto the platform for 20 s and assigned a latency 
of 180 s. Between one trail and the next, water was stirred 
to erase olfactory traces of previous swim patterns. The en-
tire procedure took sixth consecutive days, and each animal 
had three training trials per day, with a 30- to 40-min inter- 
trial interval.
3. Probe trial for retention test
  For the probe trial, each rat was placed into the water 
diagonally from the target quadrant, and for 60 s, was al-
lowed to search the water from which the platform had 
been removed. The probe trial was expressed by the ratio 
of the time spent for searching the platform in the target 
quadrant to total duration spent for swimming in the pool.
Cholineacetyltransferase (ChAT) and Acethylcholine-
sterase (AchE) immunohistochemistry
  For immunohistochemical studies, the animals were deeply 
anesthetized with sodium pentobarbital (80 mg/kg, by in-
traperitoneal injection) and perfused through the ascending 
aorta with normal saline (0.9%) followed by 300 ml (per 
rat) of 4% paraformaldehyde in 0.1 M phosphate-buffered 
saline (PBS). The brains were removed, post-fixed over-night, 
and cryoprotected with 20% sucrose in 0.1 M PBS at 4
oC. 
Coronal sections 30 μm thick were cut through the septal 
region and hippocampus using a cryostat (Leica CM1850; 
Leica Microsystems Ltd., Nussloch, Germany). The sections 
were immunostained for ChAT expression using the avi-
din-biotin-peroxidase complex (ABC) method. Briefly, the 
sections were rinsed three times for 5 min each in PBS and 
then incubated with primary rabbit anti-ChAT antibody 
(1:2,000 dilution; Cambridge Research Biochemicals Co., 
Bellingham, UK), or goat anti-AchE antibody (1：2,000 di-
lution; Santa Cruz Biotechnology Inc., CA, USA) in PBST 
(PBS plus 0.3% Triton X-100) for 72 h at 4
oC. Both secon-
dary antibodies were obtained from Vector Laboratories Co. 
(Burlingame, CA, USA) and diluted 1:200 in PBST contain-
ing 2% normal serum. To visualize immunoreactivity, the 
sections were incubated for 90 min in ABC reagent (Vecta-82 B Lee, et al
Fig. 2. Effect of PA and BER on the latencies to enter the dark 
compartment in the acquisition trial and in the retention test 
during the PAT test. ***p＜0.001 vs. the SAL group; 
#p＜0.05 and 
##p＜0.01 vs. the SCO group. 
stain Elite ABC kit; Vector Labs. Co., Burlingame, CA, USA), 
and incubated in a solution containing 3,3'-diaminobenzi-
dine (DAB; Sigma) and 0.01% H2O2 for 1 min. Images were 
captured using the AxioVision 3.0 imaging system (Carl 
Zeiss, Inc., Oberkochen, Germany) and processed using Adobe 
Photoshop (Adobe Systems, Inc., San Jose, CA, USA). The 
sections were viewed at 200×magnification, and the num-
bers of cells within 100×100-μm
2 grids were counted by ob-
servers blinded to the experimental groups. Medial septum 
and hippocampal area cells were obtained according to the 
stereotactic atlas of Paxinos and Watson [18]. The cells 
were counted in three sections per rat within the hippo-
campal area.
Enzyme-Linked Immunosorbent Assay (ELISA) in plasma
  After SCO injection for 14 days, IL-1β and IL-6 concen-
tration in blood was determined. For this study, the un-
anesthetized rats were rapidly decapitated, and the blood 
was quickly collected via the abdominal aorta. Homogeniza-
tion was carried out on ice using a tissue homogenizer and 
incubated for 1 min at 4
oC with shaking. Homogenates were 
centrifuged and supernatants were collected. Protein con-
centrations were estimated by the procedure of Taylor et 
al. [19] with BSA as the standard. The IL-1β and IL-6 con-
centration was measured by a competitive enzyme-linked 
immunoassay (ELISA) using a rabbit polyclonal IL-1β and 
IL-6 antibody (IL-1β and IL-6; R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s protocol. Sam-
ples (or standard) and conjugate were added to each well, 
and the plate was incubated for 1 h at room temperature 
without blocking. After wells were washed several times 
with buffers and proper color developed, the optical density 
was measured at 450 nm using an ELISA reader (MutiRead 
400; Authos Co., Vienna, Austria). 
Total RNA preparation and RT-PCR analysis 
  The hippocampus from each of four rats in each group 
was isolated. After decapitation, the brain was quickly re-
moved and stored at －80
oC until use. The total RNA was 
isolated from the brain sample using a TRIzol
Ⓡ reagent 
(Invitrogen Co., Carlsbad, CA, USA) and RNA was extrac-
ted according to the supplier’s instruction. Complementary 
DNA was synthesized from total RNA with a reverse tran-
scriptase (Takara Co., Shiga, Japan). Brain-derived neuro-
trophic factor (BDNF), cAMP-response element-binding 
protein (CREB), IL-1β, TNF-α, and cyclooxygenase-2 
(COX-2) mRNA expression levels were determined by the 
reverse transcription-polymerase chain reaction (RT-PCR). 
RT-PCR was performed using a PTC-100 programmable 
thermal controller (MJ Research, Inc., Watertown, MA, 
USA). All primers were designed using published mRNA 
sequences and primer design software (Primer 3; The 
Whitehead Institute for Biomedical Research, Cambridge, 
MA, USA; www.genome.wi.mit.edu) offered through their 
website. The PCR products were separated on 1.2% agarose 
gels and stained with ethidium bromide after which the den-
sity of each band was evaluated using an image- analyzing 
system (i-Max
TM, CoreBio System Co., Seoul, Korea). Com-
plementary DNA expression levels were determined by cal-
culating the relative density of each BDNF, CREB, IL-1β, 
TNF-α, and COX-2 band to glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH).
Statistical analysis
  All measurements were performed by an independent in-
vestigator blinded to the experimental conditions. Results 
in figures are expressed as mean±standard error of means 
(SE). Differences within or between normally distributed 
data were analyzed by analysis of variance (ANOVA) using 
SPSS (Version 13.0; SPSS, Inc., Chicago, IL, USA) followed 
by Tukey’s post hoc test. Statistical significance was set at 
p＜0.05. 
RESULTS
Effect of PA and its main alkaloid compound, BER 
on the passive avoidance test
  To determine whether PA or BER promotes recovery of 
memory dysfunction, PA or BER was administered to rats 
with SCO-induced impairment of memory, and their memory 
and cognitive functions were examined by the PAT (Fig. 
2). The rats in all groups were confirmed to have no physio-
logical defect (i.e., motor function defect) or intrinsic cogni-
tive impairment prior to SCO-induced impairments estab-
lished through acquisition trials without electric challenge 
in the PAT. No significant difference was found between 
the groups in the time required for acquisition trials, as 
indicated by the latencies for entering the dark compart-
ment. After acquisition, the effect of PA or BER on reten-
tion latency, indicated by the latency times for entering the 
dark compartment, was measured 24 hours after applying 
electric shock in the dark room in the PAT. Regarding re-
tention, rats in the SCO＋BER20 group (p＜0.05) and the 
SCO＋PA200 group (p＜0.01) were shown to have signifi-
cantly increased latencies for entering the dark compart-
ment compared with the SCO group. This study indicates 
that SCO injection severely impaired long-term memory, 
while the PA and BER treatment significantly attenuated 
the SCO-induced memory deficit in the PAT test. It also 
indicated that the recovery of memory impairment of rats 
in the 200 mg/kg PA-treated group was better than those 
rats in the 20 mg/kg BER-treated group, and almost com-
patible with the rats in the 0.2 mg/kg TA-treated group. Effect of PA and BER on Memory Impairment 83
Fig. 3. Time to escape (latency) during acquisition trials of hidden 
platform (A), probe trial (B), and swim speed (C) during the Morris 
water maze test. **p＜0.01 and ***p＜0.001 vs. the SAL group; 
#p
＜0.05 and 
##p＜0.01 vs. the SCO group. 
Effect of PA and its main alkaloid compound, BER 
on the water maze test
  The effect of PA or BER treatment on the swimming time 
to reach the submerged platform is illustrated in Fig. 3. 
The SAL group rapidly learned the location of the sub-
merged hidden platform and reached it within 20 s on day 
5 of the trials. The SCO group showed a marked retardation 
in escape latency, probably due to memory deficits resulting 
from SCO-induced impairment of learning and memory. 
Analysis of escape latency revealed that rats in both the 
SCO＋BER20 group and the SCO＋PA200 group had sig-
nificantly reduced swimming latency as compared with 
those in the SCO group (SCO＋BER20 group: p＜0.05 on 
day 4 and 5, and SCO＋PA200 group: p＜0.05 on day 3, 
p＜0.01 on day 4 and 5; Fig. 3A). To examine the spatial 
memory of rats, the performance in the probe trial on day 
6 was analyzed by comparing the percentage of time spent 
swimming to the expected position of platform (Fig. 3B). 
The times spent swimming around was significantly re-
duced in the rats that swam to the target area where the 
platform had been located. The repeated administration of 
SCO severely impaired spatial performance in the MWM 
test (p＜0.01). Rats in the 20 mg/kg BER-treated (p＜0.05) 
group and the 200 mg/kg PA-treated (p＜0.01) group spent 
more time around the platform area than did those in the 
SCO group. The SCO group was not significantly different 
from other groups in terms of mean swimming speed, as 
calculated by dividing the total swim distance by the la-
tency (Fig. 3C). Total distance traveled in each group was 
closely associated with escape latency in this task (data not 
shown). Based on these results, the 20 mg/kg of BER-treat-
ed and 200 mg/kg of PA-treated rats showed greater im-
provements in acquisition during the hidden platform trial 
and reached the platform quicker than the SCO-treated 
rats. PA and BER treatment significantly attenuated the 
SCO-induced deficit of learning and memory demonstrated 
in the water maze. Thus, PA-treated rats and BER-treated 
rats showed a significant amelioration in the memory re-
tention test because they spent more time in the quadrant 
where the platform was formerly located and swam over 
the former location of the platform more frequently. It also 
indicated that the swimming latency of spatial memory im-
pairment in rats receiving 200 mg/kg PA administration 
was better than those rats receiving 20 mg/kg BER admin-
istration, and almost compatible with the rats receiving 0.2 
mg/kg TA administration. 
Effect of PA and its main alkaloid compound, BER 
on septo-hippocampal choline acetyltransferase
  Following the behavioral tasks, brain tissue samples 
from the subjects were analyzed using immunohistochemi-
stry to investigate the effect of PA or BER administration 
on neurons loss due to SCO-induced memory impairment. 
ChAT immunoreactivity analysis in the septo-hippocampal 
cholinergic neurons areas are shown in Fig. 4. The brains 
of the SCO group showed significant neurons loss in the 
medical septum and hippocampal regions of septo-hippo-
campal cholinergic neurons, as compared to the SAL group 
(p＜0.001; Fig. 5A). The number of ChAT-immunoreactive 
neurons significantly increased in the medical septum re-
gion in the SCO＋BER20 group (p＜0.01) and the SCO＋
PA200 group (p＜0.01), as compared to the SCO group. Also, 
the number of ChAT-immunoreactive neurons significantly 
increased in hippocampal region in the SCO＋BER20 group 
(p＜0.05) and the SCO＋PA200 group (p＜0.05), as compared 
to the SCO group. Losses of ChAT-immunoreactivity in 
SCO-induced memory impairment rats were significantly 
restored by the PA and BER administration, and the num-
ber of ChAT-immunopositive neurons was closely similar 
to that of the control group. It also indicated that the ChAT 
activity in the septo-hippocampal cholinergic neurons in 84 B Lee, et al
Fig. 4. Representative photographs 
showing the distribution of choline 
acetyltransferase- and acetylcholine-
sterase-reactive cells in the hippo-
campus of the SAL-ChAT-MS (A), 
SCO-ChAT-MS (B), SCO＋PA200- 
ChAT-MS (C), SAL-ChAT-hippocam-
pus (D) SCO-ChAT-hippocampus (E),
SCO＋PA200-ChAT-hippocampus 
(F), SAL-AchE-CA1 (G), SCO-AchE- 
CA1 (H), SCO＋PA200-AchE-CA1 (I),
SAL-AchE-CA1 (J), SCO-AchE-CA1 
(K), and SCO＋PA200-AchE-CA1 (L) 
groups. Sections were cut coronally 
at 30 μm. Scale bar indicates 50 μm.
Fig. 5. Percentage (±SE) values of the mean number of choline acetyltransferase (ChAT)-stained neurons (A) and the density of 
acetylcholinesterase-stained neuron (B) in different hippocampal areas after the Morris water maze task. **p＜0.01 and ***p＜0.001 vs. 
the SAL group; 
#p＜0.05 and 
##p＜0.01 vs. the SCO group.
rats receiving 200 mg/kg PA administration was better 
than those rats receiving 20 mg/kg BER administration, 
and almost compatible with the rats receiving 0.2 mg/kg 
TA administration. 
Effect of PA and its main alkaloid compound, BER 
on hippocampal acetylcholinesterase
  The density of AchE-immunopositive fibers in the CA1 
and CA3 area of the rat hippocampus was significantly de-
creased in the SCO group as compared to the SAL group 
(p＜0.01; Fig. 5B). The AchE-reactive neuronal activity in 
the CA1 and CA3 area of hippocampus due to SCO-induced 
memory impairment was significantly restored in the SCO＋
BER20 group (p＜0.05) and the SCO＋PA200 group (p＜ 
0.05), as compared to the SCO group. The effect of PA and 
BER on the density of AchE reactive neurons in hippo-
campus CA3 region was similar to that in the CA1 region. 
It also indicated that the density of AchE-reactive neurons 
in the hippocampus in rats receiving 200 mg/kg PA admin-
istration was better than those rats receiving 20 mg/kg 
BER administration, and almost compatible with the rats 
receiving 0.2 mg/kg TA administration.Effect of PA and BER on Memory Impairment 85
Fig. 6. Interleukin-1 beta (IL-1β) (A) and Interleukin-6 (IL-6) (B) protein expression in rat plasma after scopolamine injection for 14 days.
*p＜0.05 and **p＜0.01 vs. the SAL group; 
#p＜0.05 vs. the SCO group. 
Fig. 7. PCR bands and their relative intensities of brain-derived neurotrophic factor (BDNF) and cAMP-response element-binding protein 
(CREB) mRNA (A), and PCR bands and their relative intensities of interleukin-1 beta (IL-1β), tumour necrosis factor (TNF)-α, and 
cyclooxygenase-2 (COX-2) mRNA (B) in the hippocampus of scopolamine-induced cognitive impairment rats. *p＜0.05 and **p＜0.01 vs. 
the SAL group; 
#p＜0.05 and 
##p＜0.01 vs. the SCO group. 
Effect of PA and its main alkaloid compound, BER 
on the IL-1β and IL-6 protein expression in the 
plasma
  The ELISA analysis demonstrated that SCO administra-
tion for 14 days significantly increased the plasma IL-1β 
and IL-6 proteins expression in the rats by 229.07% and 
161.39%, respectively. The expression of IL-1β protein in 
the plasma was markedly increased in the SCO group, as 
compared to the SAL group (p＜0.01; Fig. 6A). The expres-
sion of IL-1β protein in the plasma due to SCO-induced 
memory impairment was significantly restored in the SCO
＋BER20 group (p＜0.05) and the SCO＋PA200 group (p＜ 
0.05), as compared to SCO group. The expression of IL-6 
protein in the plasma was also markedly increased in the 
SCO group, as compared to the SAL group (p＜0.05; Fig. 
6B). The expression of IL-6 protein in the plasma due to 
SCO-induced memory impairment was significantly re-
stored in the SCO＋PA200 group (p＜0.05), as compared 86 B Lee, et al
to SCO group. It also indicated that the expression of IL-1β 
and IL-6 proteins in the plasma in rats receiving 200 mg/kg 
PA administration was better than those rats receiving 20 
mg/kg BER administration, and almost compatible with the 
rats receiving 0.2 mg/kg TA administration.
Effect of PA and its main alkaloid compound, BER 
on BDNF, CREB, IL-1β, TNF-α and COX-2 mRNA 
expression levels in the hippocampus
  The effect of PA or BER administration on BDNF, CREB, 
IL-1β, TNF-α and COX-2 mRNA expression levels in the 
rats with SCO-induced hippocampus lesions was investi-
gated using RT-PCR analysis (Fig. 7). Hippocampal BDNF 
and CREB mRNA expression in the SCO group were sig-
nificantly decreased as compared to that of the SAL group 
(p＜0.01). The decreased expression of BDNF and CREB 
mRNA in the SCO group was significantly restored in the 
SCO＋BER20 group (p＜0.05) and the SCO＋PA200 group 
(p＜0.01). It also indicated that the expression of BDNF and 
CREB mRNA in the hippocampus in rats receiving 200 
mg/kg PA administration was better than those rats receiv-
ing 20 mg/kg BER administration, and almost compatible 
with the rats receiving 0.2 mg/kg TA administration. Hippo-
campal IL-1β and TNF-α mRNA expression in the SCO 
group was significantly increased as compared to that of 
the SAL group (p＜0.05 and p＜0.01, respectively). The in-
creased expression of IL-1β mRNA in the SCO group was 
significantly restored in the SCO＋PA200 group (p＜0.05). 
The increased expression of TNF-α mRNA in the SCO 
group was also significantly restored in the SCO＋PA200 
group (p＜0.01). It also indicated that the expression of IL-1
β and TNF-α mRNA in the hippocampus in rats receiving 
200 mg/kg PA administration was better than those rats 
receiving 20 mg/kg BER administration, and almost com-
patible with the rats receiving 0.2 mg/kg TA admini-
stration. Hippocampal COX-2 mRNA expression in the SCO 
group were also significantly increased as compared to that 
of the SAL group (p＜0.01). The increased expression of 
COX-2 mRNA in the SCO group was significantly restored 
in the SCO＋PA100 group (p＜0.05) and the SCO＋PA200 
group (p＜0.05). It also indicated that the expression of 
COX-2 mRNA in the hippocampus in rats receiving 200 
mg/kg PA administration was almost compatible with the 
rats receiving 0.2 mg/kg TA administration.
DISCUSSION
  PA is well known to have multiple pharmacological activ-
ities and has been used for treating various cognitive dis-
orders and psychosomatic diseases such as stress [20]. 
Although typical prescriptions including PA are known to 
be clinically effective in alleviating memory-related symp-
toms, the underlying mechanisms of PA in those effects 
have not been investigated. A major component of PA is 
BER, which could potentially possess anti-AD effects [21]. 
Recently, some studies demonstrated that BER could inhi-
bit the expression of some inflammatory factors through the 
nuclear factor-κB (NF-κB) signaling pathway [22]. Also, 
BER can penetrate the blood-brain barrier to reach the 
striatum, cortex, and hippocampus, and thus, BER might 
act directly in brain nuclei to produce neuroprotective ef-
fects [11]. However, our results are not consistent with the 
previous studies showing that BER could inhibit memory 
impairment and expression of the inflammatory factor in-
terleukin-1β by increasing microglial activation [13]. The 
difference between our results and those of previous studies 
may result from differing effects of BER on immune and 
inflammatory factor expression in different animal modes 
of Alzheimer’s disease. 
  The present results demonstrated that repeated SCO-in-
duced dementia produced severe deficits in performance on 
tests of cognitive functioning as well as corresponding signs 
of neurodegeneration in the brain, including decreased 
ChAT and AchE activities in the hippocampus. Our results 
showed that administration of PA and BER significantly 
improved learning and memory on the PAT and it decrea-
sed the escape latency and increased the number of plat-
form crossings in the MWM test in a rat model of AD. It 
also produced increased ChAT and AchE immunoreactivity 
in septo-hippocampal cholinergic neurons areas and increa-
sed BDNF and CREB mRNA expression in the hippocam-
pus associated with the SCO-induced memory impairment 
in male rats. PA and BER also inhibited the increase in 
proinflammatory cytokines in the plasma and hippocampus 
of rats with SCO-induced deficits. 
  Our results suggest that administration of 200 mg/kg PA 
produced a significantly higher inhibitory effect on activity 
than did 20 mg/kg BER. It is known that PA contains pal-
matine and coptisine as well as BER, and previous reports 
have shown that palmatine and coptisine regulated behav-
ioral activity and had CNS effects. Thus, other alkaloids 
may also affect SCO-induced memory deficits and the chol-
inergic system.
  Chronic administration of SCO in animals transiently 
produces several deficits in learning acquisition and short- 
term memory that are considered to be similar to the chol-
inergic deficits in AD or senile CNS dysfunction [3]. The 
well-replicated amnesic effect of SCO has been interpreted 
as a principal consequence of the blockade of post-synaptic 
muscarinic M1 transmission, leading to disruption in the 
functioning of the hippocampus in working memory. Thus, 
the SCO-induced amnesic model has been widely used as 
a pharmacological model of memory dysfunction in screening 
for agents with potential cognition-enhancing effects [4]. 
  This study showed that SCO significantly shortened the 
step-through latency of the retention trial in the PAT, dem-
onstrating that the central cholinergic neuronal system 
plays an important role in learning acquisition and synaptic 
plasticity. PA and BER prolonged the step-through latency 
of the passive avoidance response that had been shortened 
by SCO. These results suggest that the anti-amnesic effect 
of PA and BER in SCO-induced memory impairment may 
be mediated by the cholinergic nervous system. 
  To confirm the effects of PA and BER on other types of 
memory, we performed the MWM test to evaluate spatial 
learning. The MWM test is a hippocampus-dependent mem-
ory task that is frequently used for examining cognitive def-
icits and demonstrating permanent spatial learning ability 
and reference memory in rodents [23]. Animals encode spa-
tial working information during the learning step, which 
then serves to guide future memory retrieval. The current 
finding that the memory deficits demonstrated by the SCO- 
impaired rats in the MWM task were more pronounced 
than were those in the SAL group were consistent with a 
previous study [24]. During the trial sessions, the PA and 
BER groups showed significantly reduced escape latency, 
enhanced cognitive performance, and amelioration of the 
memory deficits associated with SCO. In terms of average Effect of PA and BER on Memory Impairment 87
swim speeds and rest times, both indices of motor function-
ing, the SCO group did not differ significantly from the 
PA-treated and BER-treated groups, suggesting that motor 
impairment was not the primary cause of the poor perform-
ance of the SCO group in the MWM test. Thus, it is evident 
that PA and BER administration improved MWM perform-
ance by directly enhancing spatial working memory. Scores 
on the escape and the spatial probe tests of the MWM test 
are considered to primarily reflect long-term spatial memo-
ry ability. In this study, PA and BER treatment shortened 
the escape latency without affecting swimming velocity and 
extended the time spent swimming in the place where the 
platform was previously located. In the probe test, admini-
stration of PA and BER lowered the escape latency to levels 
comparable to those demonstrated by the control group and 
significantly increased the number of times that the rats 
crossed the platform location [25]. 
  Our results showed that chronic administration of SCO 
also produced severe deficits in cholinergic neuron dysfunc-
tion as well as decreased ChAT and AchE activities in the 
hippocampus, indicating neurodegeneration in the brain. 
Impairment in the hippocampus generally results in dimin-
ished spatial learning ability [23,26]. It seems likely that 
the central cholinergic neuronal system plays an important 
role in learning acquisition and synaptic plasticity [27]. The 
expression and activation of AchE and ChAT regulate the 
dynamic concentration of ACh in the cholinergic synapses 
in the brain [28]. PA and BER improved cholinergic neu-
rons in the hippocampus and continuously induced in-
creases in ChAT and AchE activities, which eventually re-
sulted in recovery of the entire cholinergic circulation path-
way [29]. According to the cholinergic hypothesis, memory 
impairment in patients with senile dementia is due to selec-
tive and irreversible deficits in cholinergic function or alter-
nation in hippocampal functioning in the brain [29]. Thus, 
cholinesterase inhibitors and ChAT activators may compen-
sate for reduced the ACh levels in brains with AD disease. 
Previous biochemical and behavioral evidence indicated 
that central cholinergic transmission declines as a result 
of SCO administration [30] and the type of dementia asso-
ciated with AD [31]. This type of decline has been closely 
associated with cognitive disturbances. It seems likely that 
the observed amelioration in the deficits in spatial learning 
capability demonstrated in the PA-treated and BER-treated 
rats were associated with the increased release of ACh. 
Thus, we propose that the beneficial effects of PA and its 
major alkaloid compound, BER, to ameliorate memory im-
pairments could be related to increase central cholinergic 
functioning. 
  On the other hand, new findings concerning the activa-
tion of BDNF and CREB as novel therapeutics have been 
reported through several basic and clinical studies [32]. The 
intentional expression of BDNF and CREB proteins in the 
brain provides a novel treatment strategy for healing mem-
ory deficits [33]. Recent experimental evidence strongly 
supports the role of BDNF in the modulation of synaptic 
function and plasticity in CNS for learning and memory 
processes, besides its actions on neuronal cell survival and 
prevention of neurodegeneration [33]. Also, there is suffi-
cient evidence that the CREB regulates the expression of 
genes involved in neuroplasticity, cell survival, and cogni-
tion [34]. The phosphorylated CREBs are able to bind to 
cAMP response elements of the target genes considered to 
be involved in long-term memory formation [35]. Thus, 
BDNF transcription, regulated by CREB, may also be a 
critical player in the adaptive neuronal responses under-
lying learning and memory function [36]. Thus, a previous 
study suggested a close correlation between reduced ex-
pression of BDNF and CREB in the hippocampus and cog-
nitive impairment [37]. SCO-induced memory deficits in-
duced significant reductions of the BDNF and CREB mRNA 
expression in the hippocampus and poor performance in the 
hippocampus-dependent tasks [38,39]. We thus proposed 
that administration of PA and BER significantly prevented 
the reduction of the BDNF and CREB mRNA expression 
induced by SCO. These findings suggested that the benefi-
cial effects of PA and BER reduces SCO-induced memory 
and learning deficits by the increase in BDNF expression 
via the CREB signaling pathway and could be related to 
increase in neuronal functioning. 
  At the same time, many studies have suggested that 
amyloid β-peptide (25-35)-induced or SCO-induced IL-1β 
and TNF-α expression is upregulated in AD [40] and that 
these cytokines may play a role in several events in the 
pathological cascade of AD [41]. These results suggest that 
inflammatory reactions may be related to the pathogenesis 
of degenerative changes and cognitive impairment [42]. In 
the present study, SCO administration caused an increase 
in the proinflammatory cytokines IL-1β and TNF-α as well 
as learning and memory deficits. PA and BER inhibited the 
increased activation of proinflammatory cytokines such as 
IL-1β and TNF-α in SCO-treated rats. 
  Many studies have suggested that the inducible gene en-
coding COX-2 is a key element that modulates the gen-
eration of proinflammatory mediators including various 
prostagladins [43]. It is known that the expression of COX-2 
and the synthesis of prostaglandin E2 (PGE2), one of its 
products, are increased in the hippocampus of AD patients, 
which may be related to the pathogenesis of the degener-
ative changes and cognitive impairments [44]. These results 
suggest that inflammatory responses to SCO injection sig-
nificantly stimulated the expression of COX-2 mRNA in the 
hippocampus through modulating the NF-κB pathway [45]. 
The increase in COX-2 expression by NF-κB activation can 
accelerate inflammatory responses and subsequently con-
tribute to learning and memory deficits. Thus, treatment 
with long-lasting COX-2 inhibitors during the initial stages 
of AD, before clinical symptoms of dementia appear, may 
suppress inflammatory responses and the synthesis of 
pro-inflammatory mediators in the brain [46]. In the pres-
ent study, PA significantly decreased SCO-stimulated beha-
vioral changes and memory disturbances through inhibition 
of COX-2 mRNA expression. Thus, we proposed that the 
anti-inflammatory effects of PA and BER significantly re-
versed impairment in spatial working memory. 
  The present study showed that repeated SCO-induced de-
mentia produced learning and memory deficits as well as 
associated degeneration of cholinergic neurons, impairment 
of neuronal function and inflammatory reactions in rats, 
as evidenced by their performances on the PAT and MWM 
tests and gene expression analysis in a rat model of AD 
disease. However, administration of PA and BER attenu-
ated these SCO-induced dementia effects, as indicated by 
improved cognitive functioning during behavioral tests and 
increases in the density of cholinergic neurons. Thus, PA 
and its major alkaloid compound, BER may be useful 
agents in preventing cholinergic dysfunction, neuronal im-
pairment, and anti-inflammatory effects such as those ob-
served in AD. 88 B Lee, et al
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